The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Research Report 2025
Synopsis
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market was valued at US$ 7633.6 million in 2023 and is anticipated to reach US$ 11190 million by 2030, witnessing a CAGR of 5.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics.
Report Scope
The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
Segment by Type
Oral Therapy
Injectable Therapy
Segment by Application
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market was valued at US$ 7633.6 million in 2023 and is anticipated to reach US$ 11190 million by 2030, witnessing a CAGR of 5.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics.
Report Scope
The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
Segment by Type
Oral Therapy
Injectable Therapy
Segment by Application
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral Therapy
1.2.3 Injectable Therapy
1.3 Market by Application
1.3.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals & Clinics
1.3.3 Home Settings
1.3.4 Ambulatory Surgical Centers (ASCs)
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Perspective (2019-2030)
2.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Growth Trends by Region
2.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Dynamics
2.3.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industry Trends
2.3.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers
2.3.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
2.3.4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Revenue
3.1.1 Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue
3.4 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Concentration Ratio
3.4.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2023
3.5 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Key Players Head office and Area Served
3.6 Key Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Solution and Service
3.7 Date of Enter into Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Breakdown Data by Type
4.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Type (2025-2030)
5 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Breakdown Data by Application
5.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)
6.2 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)
6.4 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)
7.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)
7.4 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)
9.2 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Inc.
11.1.1 Astellas Inc. Company Detail
11.1.2 Astellas Inc. Business Overview
11.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction
11.1.4 Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
11.1.5 Astellas Inc. Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction
11.2.4 Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Sanofi S.A
11.3.1 Sanofi S.A Company Detail
11.3.2 Sanofi S.A Business Overview
11.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction
11.3.4 Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
11.3.5 Sanofi S.A Recent Development
11.4 Dendreon Corporation
11.4.1 Dendreon Corporation Company Detail
11.4.2 Dendreon Corporation Business Overview
11.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction
11.4.4 Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
11.4.5 Dendreon Corporation Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Introduction
11.5.4 Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
11.5.5 Bayer AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Oral Therapy
Table 3. Key Players of Injectable Therapy
Table 4. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2019-2024)
Table 8. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2025-2030)
Table 10. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Trends
Table 11. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers
Table 12. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
Table 13. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
Table 14. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Players (2019-2024)
Table 16. Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2023)
Table 17. Ranking of Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Solution and Service
Table 21. Date of Enter into Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2019-2024)
Table 25. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2025-2030)
Table 27. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2019-2024)
Table 29. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2025-2030)
Table 31. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Astellas Inc. Company Detail
Table 47. Astellas Inc. Business Overview
Table 48. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product
Table 49. Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)
Table 50. Astellas Inc. Recent Development
Table 51. Johnson & Johnson Company Detail
Table 52. Johnson & Johnson Business Overview
Table 53. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product
Table 54. Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)
Table 55. Johnson & Johnson Recent Development
Table 56. Sanofi S.A Company Detail
Table 57. Sanofi S.A Business Overview
Table 58. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product
Table 59. Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)
Table 60. Sanofi S.A Recent Development
Table 61. Dendreon Corporation Company Detail
Table 62. Dendreon Corporation Business Overview
Table 63. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product
Table 64. Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)
Table 65. Dendreon Corporation Recent Development
Table 66. Bayer AG Company Detail
Table 67. Bayer AG Business Overview
Table 68. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product
Table 69. Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024) & (US$ Million)
Table 70. Bayer AG Recent Development
Table 71. Research Programs/Design for This Report
Table 72. Key Data Information from Secondary Sources
Table 73. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Oral Therapy Features
Figure 4. Injectable Therapy Features
Figure 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Application: 2023 VS 2030
Figure 7. Hospitals & Clinics Case Studies
Figure 8. Home Settings Case Studies
Figure 9. Ambulatory Surgical Centers (ASCs) Case Studies
Figure 10. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Report Years Considered
Figure 11. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region: 2023 VS 2030
Figure 14. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Players in 2023
Figure 15. Global Top Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue in 2023
Figure 17. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)
Figure 19. United States Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)
Figure 23. Germany Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2019-2030)
Figure 31. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)
Figure 39. Mexico Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2019-2030)
Figure 43. Turkey Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Astellas Inc. Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
Figure 46. Johnson & Johnson Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
Figure 47. Sanofi S.A Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
Figure 48. Dendreon Corporation Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
Figure 49. Bayer AG Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business (2019-2024)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
